Oneview (ASX:ONE) share price jumps 15% today. Here's why

The Oneview share price has continued to surge today, more than a week after announcing its world-first cloud-computing healthcare software.

The Oneview Healthcare PLC (ASX: ONE) share price has continued to surge today, more than a week after announcing its world-first cloud-computing healthcare software.

At the close of trade today, the Oneview share price is up 15.2% at 42 cents per share.

Oneview provides patient engagement and clinical workflow technology solutions to healthcare facilities and had a major windfall when it launched its Cloud Care Experience Platform, a platform that allows health systems to quickly adopt technology for engaging patients.

The company provides various inpatient, outpatient and clinical pathway solutions. It generates its revenue in the form of software usage and content revenue, support services, and license fees.

Geographically, Oneview operates in Ireland, the United States, Australia, and the Middle East and North Africa. It generates the majority of its revenue from the USA.

Image source: Getty Images

Why is Oneview's Cloud Care Experience Platform useful?

Oneview says that implementing a cloud-based platform for managing patients reduces non-clinical demands on care teams and optimises clinical and operational effectiveness.

The fact that Oneview's platform has had strong support from Microsoft and runs on its platform, Azure, has proven to be a key breakthrough for the company in ensuring an easy rollout into hospitals.

The strong investor response to Oneview's share price has also been due to the product's world-first nature and its release during a time of increased stress on public and private healthcare systems.

Developed with a medical centre

The CXP Cloud Enterprise platform was developed in partnership with NYU Langone Health, a leading academic medical centre in New York, which rapidly rolled out the virtual engagement platform across its facilities during the coronavirus pandemic.

NYU Langone CIO Nader Mherabi said it had arrived at a pivotal time for the healthcare industry.

COVID-19 strained resources and challenged most hospitals to examine how virtual pathways can enhance patient care.

Oneview helped us build an in-patient virtual care platform, which has been instrumental during the pandemic and will continue to be key as we deliver a new level of patient engagement.

Oneview share price snapshot

The Oneview share price has been in the red for 9 of the past 14 days, but today has seen a rapid increase in investment. On the days that the share price has jumped, it's often increased by between 15 and 30%, while declines have been far more moderate.

The Oneview share price is up more than 480% this month and 875% over the past 12 months. 

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »